Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

Business Wire

2020-11-11

Management to host a conference call and webcast at 4:30 PM ET on that day

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.

Conference Call Details
*Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time*
Toll Free:				877-407-3982
International:				201-493-6780
Conference ID:				13713171
Webcast:				http://public.viavid.com/index.php?id=142451

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.

Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006234/en/

Contacts

Media
Amanda Sellers
asellers@vergescientific.com
301-332-5574

Investors
Bruce Mackle
LifeSci Advisors. LLC
bmackle@lifesciadvisors.com
929-469-3859

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2082169064"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2082169064\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2082169064?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GyCzyJscGV76bubIxar8.A--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/4diL8zQMJ1v6Cf8GJM2LsQ--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/42c7ae0e1b8616070f1baf520fce9712","is_english":true,"pubTime":"2020-11-11 06:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2082169064","market":"us","top_or_hot":-1,"title":"Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16","media":"Business Wire","content":"<html><body><p><i>Management to host a conference call and webcast at 4:30 PM ET on that day</i></p>\n<p><a href=\"https://laohu8.com/S/NVUS\">Novus Therapeutics, Inc.</a> (\"Novus\") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.</p>\n<table cellspacing=\"0\">\n<tbody>\n<tr>\n<td colspan=\"5\" rowspan=\"1\"><p><b>Conference Call Details</b></p></td>\n</tr>\n<tr>\n<td colspan=\"5\" rowspan=\"1\"><p><b><i>Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time </i></b></p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Toll Free:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>877-407-3982</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>International:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>201-493-6780</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Conference ID:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>13713171</p></td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\"><p>Webcast:</p></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"></td>\n<td colspan=\"1\" rowspan=\"1\"><p>http://public.viavid.com/index.php?id=142451</p></td>\n</tr>\n</tbody>\n</table>\n<p><strong>About Novus Therapeutics </strong></p>\n<p>Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.</p>\n<p>Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20201110006234/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Media </b><br/>Amanda Sellers<br/>asellers@vergescientific.com <br/>301-332-5574</p>\n<p><b>Investors </b><br/>Bruce Mackle<br/>LifeSci Advisors. LLC<br/>bmackle@lifesciadvisors.com <br/>929-469-3859</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-11-11 06:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novus-therapeutics-release-third-quarter-220400084.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Management to host a conference call and webcast at 4:30 PM ET on that day\nNovus Therapeutics, Inc. (\"Novus\") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-...</p>\n\n<a href=\"https://finance.yahoo.com/news/novus-therapeutics-release-third-quarter-220400084.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/novus-therapeutics-release-third-quarter-220400084.html","article_id":"2082169064","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GyCzyJscGV76bubIxar8.A--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/4diL8zQMJ1v6Cf8GJM2LsQ--~B/aD0xMzI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/42c7ae0e1b8616070f1baf520fce9712"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2082169064","pubTimestamp":1605045840,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Management to host a conference call and webcast at 4:30 PM ET on that day\nNovus Therapeutics, Inc. ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Novus Therapeutics将于11月16号（星期一）发布2020年第三季度财报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVUS":0.9},"content_text":"Management to host a conference call and webcast at 4:30 PM ET on that day\nNovus Therapeutics, Inc. (\"Novus\") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.\n\n\n\nConference Call Details\n\n\nMonday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time \n\n\nToll Free:\n\n\n\n877-407-3982\n\n\nInternational:\n\n\n\n201-493-6780\n\n\nConference ID:\n\n\n\n13713171\n\n\nWebcast:\n\n\n\nhttp://public.viavid.com/index.php?id=142451\n\n\n\nAbout Novus Therapeutics \nNovus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.\nFollow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20201110006234/en/\nContacts\nMedia Amanda Sellersasellers@vergescientific.com 301-332-5574\nInvestors Bruce MackleLifeSci Advisors. LLCbmackle@lifesciadvisors.com 929-469-3859","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}